主页 文献库文献详情
PMID: 25103822 已发表 · ppublish 英语

Variation in mutation spectrum partly explains regional differences in the breast cancer risk of female BRCA mutation carriers in the Netherlands.

Vos Janet R, Teixeira Natalia, van der Kolk Dorina M, Mourits Marian J E, Rookus Matti A, van Leeuwen Flora E, Collée Margriet, van Asperen Christi J, Mensenkamp Arjen R, Ausems Margreet G E M, van Os Theo A M, Meijers-Heijboer Hanne E J, Gómez-Garcia Encarna B, Vasen Hans F, Brohet Richard M, , van der Hout Annemarie H, Jansen Liesbeth, Oosterwijk Jan C, de Bock Geertruida H

摘要

We aimed to quantify previously observed relatively high cancer risks in BRCA2 mutation carriers (BRCA2 carriers) older than 60 in the Northern Netherlands, and to analyze whether these could be explained by mutation spectrum or population background risk.,This consecutive cohort study included all known pathogenic BRCA1/2 carriers in the Northern Netherlands (N = 1,050). Carrier and general reference populations were: BRCA1/2 carriers in the rest of the Netherlands (N = 2,013) and the general population in both regions. Regional differences were assessed with HRs and ORs. HRs were adjusted for birth year and mutation spectrum.,All BRCA1 carriers and BRCA2 carriers younger than 60 had a significantly lower breast cancer risk in the Northern Netherlands; HRs were 0.66 and 0.64, respectively. Above age 60, the breast cancer risk in BRCA2 carriers in the Northern Netherlands was higher than in the rest of the Netherlands [HR, 3.99; 95% confidence interval (CI), 1.11-14.35]. Adjustment for mutational spectrum changed the HRs for BRCA1, BRCA2 <60, and BRCA2 ≥60 years by -3%, +32%, and +11% to 0.75, 0.50, and 2.61, respectively. There was no difference in background breast cancer incidence between the two regions (OR, 1.03; 95% CI, 0.97-1.09).,Differences in mutation spectrum only partly explain the regional differences in breast cancer risk in BRCA2 carriers, and for an even smaller part in BRCA1 carriers.,The increased risk in BRCA2 carriers older than 60 may warrant extension of intensive breast screening beyond age 60.

文献信息
期刊
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
期刊简称
Cancer Epidemiol Biomarkers Prev
发表日期
2015-07-08
收录日期
2014-11-04
更新日期
2014-11-04
语言
英语
国家/地区
United States
NLM ID
9200608
分析服务
分析服务

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: product@genelibs.com